

Bond University
Research Repository



Examining the health effects and bioactive components in *Agaricus bisporus* mushrooms: A scoping review

Blumfield, Michelle ; Abbott, Kylie; Duve, Emily ; Cassettari, Tim; Marshall, Skye; Fayet-Moore, Flavia

Published in:
Journal of Nutritional Biochemistry

DOI:
[10.1016/j.jnutbio.2020.108453](https://doi.org/10.1016/j.jnutbio.2020.108453)

Licence:
CC BY-NC-ND

[Link to output in Bond University research repository.](#)

Recommended citation(APA):
Blumfield, M., Abbott, K., Duve, E., Cassettari, T., Marshall, S., & Fayet-Moore, F. (2020). Examining the health effects and bioactive components in *Agaricus bisporus* mushrooms: A scoping review. *Journal of Nutritional Biochemistry*, 84, [108453]. <https://doi.org/10.1016/j.jnutbio.2020.108453>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.



REVIEWS: CURRENT TOPICS

Examining the health effects and bioactive components in *Agaricus bisporus* mushrooms: a scoping review☆

Michelle Blumfield^a, Kylie Abbott^{a,b}, Emily Duve^c, Tim Cassettari^d, Skye Marshall^{a,e}, Flavia Fayet-Moore^{f,*}

^aBNutrDiet (Hons), PhD, Nutrition Research Australia, Sydney, New South Wales, Australia

^bNutraceuticals Research Group, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia

^cBPESS, MPH, Nutrition Research Australia, Sydney, New South Wales, Australia

^dBSc(Hons), BAppSc, Nutrition Research Australia, Sydney, New South Wales, Australia

^eBond University, Nutrition and Dietetics Research Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia

^fBSc(Hons), MNutrDiet, PhD, Nutrition Research Australia, Sydney, New South Wales, Australia

Received 8 March 2020; received in revised form 19 May 2020; accepted 8 June 2020

Abstract

There is evidence from both *in vitro* and animal models that the consumption of edible mushrooms has beneficial effects on health. It is unclear whether similar effects exist in humans and which bioactive compounds are present. This review synthesises the evidence on the world's most commonly consumed mushroom, *Agaricus bisporus* to (i) examine its effect on human health outcomes; and (ii) determine the nutrient density of its bioactive compounds, which may explain their health effects. A systematic literature search was conducted on the consumption of *A. bisporus*, without date and study design limits. Bioactive compounds included ergosterol, ergothioneine, flavonoids, glucans and chitin. Two authors independently identified studies for inclusion and assessed methodological quality. Beneficial effects of *A. bisporus* on metabolic syndrome, immune function, gastrointestinal health and cancer, with the strongest evidence for the improvement in Vitamin D status in humans, were found. Ultraviolet B (UVB) exposed mushrooms may increase and maintain serum 25(OH)D levels to a similar degree as vitamin D supplements. *A. bisporus* contain beta-glucans, ergosterol, ergothioneine, vitamin D and an antioxidant compound usually reported as flavonoids; with varying concentrations depending on the type of mushroom, cooking method and duration, and UVB exposure. Further research is required to fully elucidate the bioactive compounds in mushrooms using vigorous analytical methods and expand the immunological markers being tested. To enable findings to be adopted into clinical practice and public health initiatives, replication of existing studies in different population groups is required to confirm the impact of *A. bisporus* on human health.

© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Keywords: Systematic review; *Agaricus bisporus*; Mushroom; Health; Human; Bioactive

Contents

1. Introduction 2
2. Methods 2
2.1. Eligibility criteria 2
2.2. Search strategy 3

Abbreviations: 25(OH)D₂, 25-Hydroxyvitamin D₂; 25(OH)D, 25-Hydroxyvitamin D; BBM, brown button mushrooms; CE, catechin equivalents; CG, comparator group; CGEs, cyanidin-3-glucoside equivalents; d, days; f, female; GAE, gallic acid equivalents; g, grams; Hb, haemoglobin; HDL, high density lipoprotein cholesterol; HMW, high molecular weight; H₂, hydrogen; IgA, immunoglobulin A; IgG, immunoglobulin G; IL, interleukin; IU, international units; IG, intervention group; kcal, kilocalorie; LDL, low density lipoprotein cholesterol; LMW, low molecular weight; MetS, metabolic syndrome; NA, not applicable; OR, odds ratio; ORAC, oxygen radical absorbance capacity; PCV, packed cell volume; iPTH, parathyroid hormone; PSA, prostate specific antigen; QE, quercetin equivalents; Qct, quercetin; RCT, randomised controlled trial; RBC, red blood cells; RE, rutin equivalents; sIgA, secretory immunoglobulin A; sCML, serum carboxymethyl-lysine; sMG, serum methylglyoxal; TNF, tumour necrosis factor; UV, ultraviolet; UVB, ultraviolet B; WBC, white blood cells; w/w, weight per weight; WBM, white button mushrooms

* Prospero: This study was prospectively registered (still awaiting processing). Disclaimer: Horticulture Innovation provided top line suggestions on the proposed review methodology; but had no contribution to the draft analysis, interpretation of results or drafting of the manuscript. Funding: This project has been funded by Hort Innovation, using the Mushroom Fund research and development levy and contributions from the Australian Government. Hort Innovation is the grower-owned, not-for-profit research and development corporation for Australian horticulture.

* Corresponding author at: Level 10, 20 Martin Place, Sydney, New South Wales, Australia.

E-mail address: flavia@nraus.com (F. Fayet-Moore).

2.3.	Selection process	3
2.4.	Data extraction	9
3.	Results	9
3.1.	Description of studies	9
3.1.1.	Health outcomes.	9
3.1.2.	Bioactive compounds	9
3.2.	Impact of <i>A. bisporus</i> mushroom intake on human health	9
3.2.1.	Serum vitamin D	9
3.2.2.	Inflammatory markers.	9
3.2.3.	Satiety	13
3.2.4.	Gastrointestinal health	13
3.2.5.	Cancer	13
3.2.6.	Metabolic markers.	13
3.2.7.	Immune function	14
3.3.	Concentration of bioactive compounds in <i>A. bisporus</i>	14
3.3.1.	Flavonoids	14
3.3.2.	Ergosterol and vitamin D	14
3.3.3.	Ergothioneine	14
3.3.4.	Glucans	14
3.3.5.	Chitin	14
4.	Discussion	14
4.1.	Implications for future research	15
4.2.	Limitations	15
5.	Conclusion.	16
	Acknowledgements	16
	Appendix A. Supplementary data	16
	References	16

1. Introduction

Although commonly regarded and consumed as a vegetable, mushrooms are members of the *Fungi* kingdom and offer a unique nutritional profile. Biologically distinct to both plants and animals, mushrooms are rich in micronutrients that are normally found in vegetables, meats and grains [1]. These include riboflavin, niacin, pantothenic acid, copper, phosphorus, selenium, fibre-associated monosaccharides and polysaccharides, and the sulphur-containing amino acid ergothioneine [1,2]. Mushrooms are one of the only natural vegetarian sources of both vitamin B₁₂, which is bacteria-derived [3], and vitamin D, which is produced by the conversion of ergosterol to ergocalciferol after exposure to ultraviolet (UV) light [4].

There is a growing body of evidence that suggests consuming several mushroom species, either as a food or as extracts, may improve physical and mental health [5,6]. Mushrooms are rich in bioactive compounds, particularly ergothioneine, ergosterol, vitamin D, beta-glucan and selenium, and these bioactive compounds have been favourably linked to immune function [7,8], glycaemic control [9,10], weight management [11], lipid profile [12,13], blood pressure [14], bone density [15], gut health [16], cancer [17,18] and cognitive function [19]. These health benefits are thought to be largely a result of the enhancement of cellular immunity to produce immunomodulatory, anti-carcinogenic, anti-microbial and hypocholesterolemic effects [5], and due to their effects on the gastrointestinal microbiota [19].

Despite the growing body of evidence linking mushrooms' nutritional uniqueness to beneficial health effects, existing narrative reviews have found limited evidence in human studies. In 2012, Roupas et al. [5] concluded that while mushrooms of many different species demonstrated numerous health benefits within *in vitro* and *in vivo* animal models, there was insufficient evidence to confirm similar effects in humans due to limitations in study design, sample size and the indirectness of the evidence [5]. Other narrative reviews investigating the role of beta-glucans in mushrooms [20] and immunomodulatory activities of mushroom polysaccharides [21]

have also found limited research in humans. Since these narrative reviews were published, interest into the therapeutic properties of edible mushrooms in human models has grown. Therefore, a broad systematic synthesis of the evidence reporting the health effects of edible mushrooms in humans and their bioactive compounds that support these effects is warranted.

Due to the large variety of mushroom species available for human consumption, a focus on those that are most abundant and frequently consumed by humans will have the greatest translational value. The most commonly consumed mushrooms worldwide belong to the *Agaricus bisporus* species, which includes white button mushrooms (WBM), brown button mushrooms (BBM), portobello and cremini mushrooms [1]. Therefore, the aim of this scoping literature review was to synthesise the evidence on *A. bisporus* mushrooms to (i) examine its effect on human health outcomes; and (ii) determine the nutrient density of its bioactive compounds, which may explain their health effects.

2. Methods

The review protocol was developed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [22], PRISMA Extension for Scoping Reviews (PRISMA-ScR) [23] and was prospectively registered at PROSPERO (still awaiting processing).

2.1. Eligibility criteria

Table 1 highlights the eligibility criteria for the study selection. Studies were deemed eligible if they were original primary research articles conducted in human populations, reported on whole or processed (e.g. dried extract) mushrooms from the *A. bisporus* species, were consumed orally, and reported a health outcome. All physical and mental health outcomes were considered for inclusion. Prospective cohort and cross-sectional studies on health outcomes in humans

Table 1
Inclusion and exclusion criteria for the selection of studies

Inclusion criteria	Exclusion criteria
Studies on <i>A. bisporus</i> mushrooms in human populations of any age and health effect, without date limits	Studies published in languages other than English
Studies using <i>A. bisporus</i> mushrooms in whole or processed (e.g. dried extract) form	Studies where <i>A. bisporus</i> mushrooms were not consumed orally
Studies conducted in any country	Studies in animals
Any study design	Studies in duplicate populations
Studies reporting data in a format that enabled data specific to mushrooms to be extracted	Lack of a random sample
Studies reporting ergosterol, ergothioneine, flavonoids, bioactive polysaccharides (alpha and beta glucans) and chitin in <i>A. bisporus</i> mushrooms	Studies solely reporting other bioactive compounds in <i>A. bisporus</i> mushrooms

were considered if the dietary intake from mushrooms was measured, even if the mushroom type (e.g. whole mushroom or extract) was unspecified. Studies reporting on bioactive compounds were also included if they reported on *A. bisporus* mushrooms and measured ergosterol, ergothioneine, flavonoids, glucans (alpha- or beta-glucans) or chitin.

2.2. Search strategy

A systematic search for publications was conducted (25th June 2019), using the electronic databases MEDLINE, EMBASE, Scopus, CINHAL and The Cochrane Library, without date limits (Table S1). To identify publications that reported on the consumption of *A. bisporus* mushrooms, the following keywords were searched (with special

features in parentheses): Agaricus (exp/), Agaricus bisporus (exp/), A bisporus (exp/), white button mushroom (exp/), button mushroom (exp/), common mushroom (exp/), cultivated mushroom (exp/), champignon (exp/), cremini (exp/), cremini (exp/), portobello (exp/) (Table S1). Keywords were searched for as free text in the title, abstract and subject headings. Study population and outcomes records were combined using the Boolean operator "AND". Additional publications were identified from references in original papers.

2.3. Selection process

All records identified were first assessed for eligibility based on information contained in the title, abstract, and description/MeSH heading by two independent reviewers (KA, ED, TC or FFM), after




Fig. 1. PRISMA study flow chart.

Table 2
Studies using *Agaricus bisporus* mushrooms or extracts derived from *Agaricus bisporus* mushrooms and measuring health outcomes in humans

Author, year, country	Study aim	Study Design, sample size (n: IG/CG)	Study duration	Population (age, %female, health condition)	Exposure	Outcome/s Measured	Results (↑↓↔)	Adverse effects/limitations	Conclusions	Study quality (+ 0 -)
Vitamin D Stephens, 2012, USA	To evaluate the effects of consuming UV-exposed white button mushrooms (A. bisporus) on the vitamin D status of healthy adults.	Parallel, double-blind n: 9/10/10 (8.8 µg D ₂ /17.1 µg D ₂ /control) (3% attrition)	6 w	31±11 y 58% f Healthy	Intervention: UV-exposed cooked mushrooms (87.9 g/day) delivering 8.8 µg OR 17.1 µg D ₂ /day Comparator: Non UV-exposed cooked mushrooms (87.9 g/day)	8.8 µg D ₂ /day: Serum 25(OH) D₂ ↑ (P<.05) Serum 25(OH)D ₃ ↔ Serum 25(OH)D (total) ↔ Serum 2,4,2,5 (OH)D ₃ ↔ 17.1 µg D ₂ /day: Serum 25(OH) D₂ ↑ (P<.05) Serum 25(OH) D₃ ↓ (P<.05) Serum 25(OH)D (total) ↔ Serum 2,4,2,5 (OH)D ₃ ↔	No adverse effects. No significant difference in the vitamin D ₂ content of raw mushrooms (P=.41)	Ergocalciferol was absorbed and metabolised to 25 (OH)D ₂ but did not affect vitamin D status, because 25OHD ₃ decreased proportionally.	+	
Keegan, 2013, USA	To compare effectiveness at increasing and maintaining vitamin D status of dried white button mushroom extract and supplemental vitamin D ₃ and vitamin D ₂ .	Parallel, 3-arm 2CG n: 14/8/3 (17% attrition)	11G, 12 w	35 y 75% f Healthy	Intervention: Dried white button mushroom extract (2000 IU D ₂ /day) Comparator: Supplement 2000 IU D ₂ /day OR 2000 IU D ₃ /day	Serum 25(OH)D (total) ↑ (P<.001) ^a Serum 25(OH) D₂ ↑ (P<.001) ^a Not reported	No adverse effects.	Consumption of mushrooms containing D ₂ was as effective at increasing and maintaining total serum 25(OH)D levels as supplemental vitamin D ₂ and D ₃ .	-	
Urbain, 2011, Germany	To investigate the bioavailability of vitamin D ₂ from UV-exposed mushrooms in humans, in comparison to a vitamin D ₂ supplement.	Parallel, single-blind, 3-arm (2IG, 1CG) n: 8/9/9 (8% attrition)	3-5 w	31 ± 6 y 65% f Healthy	Intervention: UV-exposed cooked mushrooms (28,000 IU D ₂ /day) OR Non-UV-exposed cooked mushrooms (60 IU D ₂ /day+28,000 IU D ₂ /day supplement) Comparator: Non-UV-exposed cooked mushrooms (60 IU D ₂ /day + placebo supplement)	28,000 IU D ₂ /day: Serum 25(OH)D (total) ↑ (P<.001) Serum Calcium ↔ Serum iPTH ↔ 60+28,000 IU D ₂ /day: Serum 25(OH)D (total) ↑ (P<.001) Serum Calcium ↔ Serum iPTH ↔	No adverse effects.	Vitamin D ₂ -enhanced button mushrooms via UV exposure was effective in improving vitamin D status in young, healthy adults.	+	
Shaney, 2014, USA	To determine if supplementation with mushroom powder would enhance skeletal muscle function and attenuate exercise-induced muscle damage in low vitamin D status high school athletes.	Parallel, double-blind, 2-arm (1IG, 1CG) n: 17/17 (3% attrition)	6 w	16± 0 y 0% f Vitamin D insufficient athletes	Intervention: UV-exposed powdered mushroom (600 IU D ₂ /day) Comparator: Placebo	Serum 25(OH)D (total) Serum 25(OH)D₂ Serum 25(OH) D₃ ↑ (P=.004) ↑ (P<.0001) ↓ (P<.0001)	No adverse effects.	600 IU/d vitamin D ₂ increased 25 (OH)D ₂ with a concomitant decrease in 25(OH)D ₃ , with no effect on muscular function or exercise-induced muscle damage in high school athletes.	0	

Inflammation Calvo, 2016, USA	To estimate the impact of adding white button mushrooms to daily diet on known T2D risk factors.	Parallel, 4-arm*** n: 37	16 w	48 y 65% f Mets	UV - exposed cooked mushrooms (100 g/day) Comparator: Supplement 1242 IU D ₃ /day OR 7320 IU D ₃ /day SMC	Serum ergothioneine ORAC 8-isoprostane Adiponectin Leptin sCML sMG	↑ (P≤.01) ↑ (P=.03) ↔ ↑ (P=.03) ↔ ↓ (P≤.01) ↓ (P≤.01)	No adverse effects.	Consuming white button mushrooms was associated with increased ergothioneine, lower circulating oxidative stress factors and higher serum adiponectin and ORAC. No adverse effects.	+
Volman, 2010, Netherlands	To evaluate the effects of consuming α-glucans in hypercholesterolemic subjects.	Parallel, double-blind n: 26/30 (0% attrition)	5 w (2 w run-in)	57± 8 y 42.9% f	Hypercholesterolemic ∅ Th1 cytokines: **IFNγ **IL-12 **IL-2 Th2 cytokines: **IL-13 **IL-4	Intervention: 200 mL juice/day containing 5 g/day α-glucans extracted from white button mushrooms Comparator: 200 mL juice/day with 0 g α-glucans	*IL-1β *IL-6 *TNFα *IL-10 *IL-17 ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔	↔ ↔ ↓ (P=.017) ↔ ↔	Consumption of A. bisporus α-glucans lowered LPS-induced TNFα production, whereas no effect on IL-1β and IL-6 was observed. No obvious Th1–Th2 skewing by PHA-stimulated PBMCs was observed. However, we observed a trend towards a decreased production of IL-12 and IL-10. No significant changes in kidney or liver function.	
Serum creatinine Serum ALT Serum AST Serum GGT Serum CPT Serum APT S e r u m Bilirubin Weigand-Heller, 2012, USA	To evaluate the bioavailability of ergothioneine using a dose-response, postprandial time-course design.	Cross-over, 2-arm (1IG, 1CG) n: 10/10 (0% attrition)	3 d (3 d washout)	27± 3 y 0% f Healthy	Intervention: Powdered mushroom (8 g/day OR 16 g/day) Comparator: Placebo	CRP Cholesterol HDL LDL Triglycerides Glucose ORAC (total) Ergothioneine	↔ ↔ ↔ ↔ ↔ ↔ ↓ (P<.05) ↑ (P<.05)	No adverse effects.	Ergothioneine was bioavailable after consuming mushrooms and a trend in the postprandial triglyceride response indicated that there was a blunting effect after both the 8 g and 16 g doses. ORAC total values decreased after the 8 g and 16 g mushroom meal.	∅
Satiety Hess, 2017, USA	To compare satiety and food intake differences between mushroom and meat consumption.	Cross-over, 2-arm (1IG, 1CG) n: 35/35 (9% attrition)	10 d (10 d washout)	23± 4 y 53% f Healthy	Intervention: Cooked mushroom meal (226 g/day) Comparator: Cooked beef meal (28 g/day)	Satiety Energy intake	↑ (P=.05) ↔	No adverse effects.	Mushroom meal had a positive effect on satiety, but no effect on energy intake.	∅

(continued on next page)

Table 2
(continued)

Author, year, country	Study aim	Study Design, sample size (n: I/G/CG)	Study duration	Population (age, %female, health condition)	Exposure	Outcome/s Measured	Results (↑↓↔)	Adverse effects/ limitations	Conclusions	Study quality (+ ∅ -)
Cheskin, 2008, USA	To investigate how substituting mushrooms for beef in a test lunch affected energy intake, fat intake, palatability, appetite, satiety and satiety in normal weight, overweight and obese adults.	Cross-over, 2-arm n: 76/76 (29% attrition)	4 d (3 d washout)	36 y 67% f Healthy	Intervention: Cooked mushroom meal (339 kcal/day) Comparator: Cooked beef meal (783 kcal/day)	Satiety Satiation Fat intake Energy intake Appetite	↔ ↔ ↓ (P<.0001) ↓ (P<.0001) ↔	No adverse effects.	Energy intakes were higher during meat lunches than mushroom lunches. Total daily energy and fat intake were greater in the meat than in the mushroom condition. Palatability, appetite, satiety and satiety did not differ.	∅
Cancer Lee, 2013, China	To investigate the association between mushroom consumption and risk of epithelial ovarian cancer.	Case-control, retrospective n: 500/500	2 y	59 ± 6 y 100% f Healthy (controls) Ovarian cancer (cases)	Exposure: White button mushroom consumption	Ovarian cancer	↓ (OR=0.68)	N/A	Ovarian cancer patients consumed less mushrooms than controls. Apparent reductions in cancer risk were found at high levels of intake, especially for white button mushroom for women consuming >2 g/day.	+
Twardoski, 2015, USA	To evaluate the effects of white button mushroom powder on serum PSA levels and determine the tolerability.	Phase I, clinical dose-escalation n: 36	10 m (1–58 m)	68 y 0% f Elevated PSA	Treatment: Powdered mushroom (4,6,8,10,12,14 g/day)	Serum PSA Androgens MDSCs IL-15	↓ (n=13, 36%)	Abdominal bloating	White button mushroom powder therapy was associated with declining PSA levels in some patients.	+
Gastrointestinal Hess, 2018, USA	To assess mushroom consumption compared to meat on gastrointestinal tolerance, short chain fatty acid (SCFA) production, laxation, and faecal microbiota.	Cross-over, 2-arm (1IG, 1CG) n: 35/35 (9% attrition)	10 d (10 d washout)	23 ± 4 y 53% f Healthy	Intervention: Cooked mushroom meal (226 g/day) Comparator: Cooked beef meal (28 g/day)	Breathe hydrogen Stool frequency Stool consistency Faecal pH F a e c a l w e i g h t SCFA	↔ ↔ ↔ ↔ ↑ (P=.002) ↔	No adverse effects.	The mushroom diet resulted in higher average stool weight and a different faecal microbiota composition compared to the meat diet, with greater abundance of Bacteroidetes lower abundance of Firmicutes. Ingesting champignon extract improved halitosis and body and faecal odour. Results suggest the effectiveness of champignon extract in alleviating odours is dose-dependent, i.e., it increases with the dosage.	∅
Nishihira, 2017, Japan	To investigate whether ingesting champignon extract daily improved halitosis and body and faecal odour.	Parallel, double-blind, 4-arm (3IG, 1CG) n: 20/20/20/20 (4% attrition)	4 w	64 ± 7 y 51% f Probiotic halitosis, body or faecal odour	Intervention: Champignon extract (50 mg/day OR 500 mg/day OR 1000 mg/day) Comparator: 0 mg/day	50 mg/day: Halitosis Pillow odour Pyjama odour Faecal odour Bowel movement regularity Strain during bowel	↔ ↔ ↓ (P=.003) ↓ (P=.001) ↔ ↓ (P=.005) ↔	No adverse effects.	Ingesting champignon extract improved halitosis and body and faecal odour. Results suggest the effectiveness of champignon extract in alleviating odours is dose-dependent, i.e., it increases with the dosage.	-

Author, year, country	Study aim	Study Design, sample size (n: I/G/CG)	Study duration	Population (age, %female, health condition)	Exposure	Outcome/s Measured	Results (↑↔↓)	Adverse effects/ limitations	Conclusions	Study quality (+ ∅ -)
↓ (P=.001) ↔ ↓ (P=.004) ↓ (P=.001) ↔ ↓ (P=.005) ↔						<p>movements Sensation of residual stools 500 mg/day: Halitosis Pyjama odour Faecal odour Bowel movement regularity Strain during bowel movements Sensation of residual stools Pyjama odour Faecal odour Bowel movement regularity Strain during bowel movements Sensation of residual stools</p>	<p>↓ (P=.001) ↓ (P=.003) ↓ (P=.004) ↓ (P=.001) ↔ ↓ (P=.005) ↔</p>			
Cholesterol Abd-alwahad, 2018, Iraq	To investigate the physiological and biological effects of eating mushrooms cooked in olive oil.	Parallel, non-randomised, 2-arm n: 25/25	30 d	Not reported.	Intervention: Cooked mushroom (2 g/kg body weight/day) Comparator: Usual diet	Glucose Cholesterol HDL LDL Triglycerides Body weight Urea Uric acid WBC RBC Hb PCV Cholesterol HDL LDL Triglycerides	<p>↓ (P<.05) ↓ (P<.05) ↑ (P<.05) ↓ (P<.05) ↓ (P<.05) ↔ ↔ ↑ (P<.05) ↑ (P<.05) ↔ ↔ ↔ ↔ ↔</p>	No adverse effects.	A. bisporus cooked in olive oil reduces harmful lipids, glucose and enhances the blood cells.	–
Weigand-Heller, 2012, USA	To evaluate the bioavailability of ergothioneine using a dose-response, postprandial time-	Cross-over, 2-arm (1IG, 1CG) n: 10/10 (0% attrition)	3 d (3 d washout)	27±3 y 0% f Healthy	Intervention: Powdered mushroom (8 g/day OR 16 g/day) Comparator: Placebo	Cholesterol HDL LDL Triglycerides	<p>↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔ ↔</p>	No adverse effects.	Ergothioneine was bioavailable after consuming mushrooms and a trend in the	∅

(continued on next page)

Author, year, country	Study aim	Study Design, sample size (n: IG/CG)	Study duration	Population (age, %female, health condition)	Exposure	Outcome/s Measured	Results (↑↓↔)	Adverse effects/ limitations	Conclusions	Study quality (+ 0 -)
course design.										
T2D risk management Calvo, 2016, USA	To estimate the impact of adding white button mushrooms to daily diet on known T2D risk factors.	Parallel, 4-arm*** n: 37	16 w	48 y 65% f MetS	Intervention: UV-exposed cooked mushrooms (100 g/day) Comparator: 8-isoprostone Supplement 1242 IU D ₃ /day OR 7320 IU D ₃ /day	Serum 25(OH)D (total) Serum ergothioneine ORAC 8-isoprostone Adiponectin Leptin sCML sMG	↔ ↑ (P≤.01) ↑ (P=.03) ↔ ↑ (P=.03) ↔ ↓ (P≤.01) ↓ (P≤.01)	No adverse effects.	postprandial triglyceride response indicated that there was a blunting effect after both the 8 g and 16 g doses. Consuming white button mushrooms was associated with increased ergothioneine, lower circulating oxidative stress factors and higher serum adiponectin and ORAC and thus improved risk markers of diabetes.	+
Immunological Jeong, 2012, Australia	To investigate the effect of dietary intake of white button mushrooms on salivary IgA (sIgA) secretion in healthy subjects.	Parallel, 2-arm (1IG, 1CG) n: 12/8 (20% attrition)	7 d	42 ± 12 y 50% f Healthy	Intervention: Cooked mushrooms (100 g/day) Comparator: Usual diet	sIgA: osmality sIgA secretion rate s I g A concentration IgG secretion rate I g G concentration	↑ (P=.0012) ↑ (P<.0005) ↑ (P<.0005) ↔ ↔	No adverse effects.	Consuming white button mushrooms accelerates sIgA secretion, thereby indicating its potential health benefits for improving mucosal immunity.	+

IG, intervention group; CG, comparator group; UV, ultraviolet; PSA, total serum prostate-specific antigen; MetS, metabolic syndrome; 25(OH)D, 25-hydroxyvitamin D; IL, interleukin; iPTH, parathyroid hormone; TNF α , tumour necrosis factor alpha; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; WBC, white blood cells; RBC, red blood corpuscles; Hb, haemoglobin; PCV, packed cell volume; ORAC, oxygen radical absorbance capacity; sCML, serum carboxymethyl-lysine; sMG, serum methylglyoxal; sIgA, secretory immunoglobulin A; IgG, immunoglobulin G; d, days; w, weeks; m, months; y, years; f, female; IU, international unit; \uparrow , significant increase compared with control; \downarrow , significant decrease compared with control; \leftrightarrow , no significant change compared with control; Study quality +, positive; 0, neutral; -, negative; * ex-vivo LPS-stimulated cytokine production in peripheral mononuclear blood cells (PBMC); ** PHA-induced T-cell proliferation in PBMC; *** 4-arm pooled analysis; a, significant from baseline.

which the inclusion and exclusion criteria were applied (Table 1). This process was completed using Covidence systematic literature review software [Veritas Health Innovation, Melbourne, Australia] [24]. The full text of all studies that appeared to meet the eligibility screening were retrieved and subjected to a second assessment for relevance by the same two reviewers (Table 1). Any difference in assessments that arose between reviewers was discussed in the first instance or resolved by a third independent reviewer (FFM).

Human research studies were then assessed for methodological quality in duplicate by two independent reviewers (KA and ED) using the Quality Criteria Checklist for Primary Research in the Academy of Nutrition and Dietetics Evidence Analysis Manual [25]. The Quality Criteria Checklist included four relevance questions that addressed applicability to practice and 10 validity questions that addressed scientific reliability, including confounding, study quality and heterogeneity. The Quality Criteria Checklist enabled a systematic, objective rating (positive, negative or neutral) to be given to each study and was used to confirm agreement among independent reviewers. 'Positive' studies were of the highest quality, with most answers to the validity questions being positive, followed by 'neutral' studies. 'Negative' studies were of the lowest quality, with most of the answers to the validity questions being negative. Once again, any difference in assessments were resolved, if necessary, by a third independent reviewer (FFM). The internal validity of studies which reported biochemical analysis of mushrooms was not performed as critical appraisal tools do not exist for this study design.

2.4. Data extraction

Data were extracted from all included studies into a Microsoft Excel [Version 1908; Excel for Office 365] spreadsheet by one investigator (KA or ED) and checked for accuracy by another investigator (KA or ED). Data extracted were study and participant characteristics, baseline, follow-up, washout period, run-in period, test product, control product, dosage, measurement method, change in outcome, and *P*-value for between group comparisons. Data extracted for bioactive studies included source of mushrooms, whether mushrooms were cultivated or wild, storage conditions, extraction and measurement technique used, amount of the bioactive reported and units of measurement. For studies reporting ergosterol, vitamin D was also extracted if reported. Original authors were contacted to confirm any missing data [26–28]. If original authors could not be contacted, data were retrieved using manuscript figs. [27] or excluded [26,28].

3. Results

3.1. Description of studies

The systematic search strategy identified 9811 records, of which 68 were eligible for inclusion ($n=15$ human studies, $n=53$ biochemical studies; Fig. 1).

3.1.1. Health outcomes

A total of 15 human trials reported on consumption of *A. bisporus* mushrooms and physical health outcomes [29–43], and none reported on mental health or cognitive function. The study characteristics and methodological quality of these included studies are shown in Table 2. The majority (73%) of studies were randomised controlled trials (RCTs) [29–36,39,40,43]. Other study designs included a non-RCT [41], a secondary analysis of a RCT which presented pooled data from two intervention groups in a pre-post study design format [42], a Phase 1 Clinical trial [38], and a retrospective case-control study [37]. The reported health outcomes were vitamin D status (4 studies) [29–32], inflammation (2 studies) [33,34], satiety (2 studies) [35,40], cancer (2 studies) [37,38], gastrointestinal health (2 studies) [39,40],

cholesterol [34,41], diabetes risk factors [42], and immunology [43]. Studies were mainly conducted in the United States of America (USA) (9 studies) [29,30,32,34–36,38,39,42], and others were from Germany [31], Netherlands [33], China [37], Japan [40], Iraq [41], and Australia [43]. Only one study reported minor adverse effects (abdominal bloating), but had no participant withdraw.

Studies were mainly conducted in adults, with one study on male teenage athletes [32]. Most of the intervention studies used 'healthy' populations (8 studies) [29–31,34–36,39,43], with the remaining conducted in adults with hypercholesterolemia [33], metabolic syndrome [42], insufficient Vitamin D levels [32], older adults with problematic halitosis and body odour [40], and cancer [37,38] (Table 2).

Using the Quality Criteria Checklist for Primary Research (Table 2), six studies received a positive quality rating (*i.e.* defined as having a high level of internal validity and low risk of bias across the study) [29,31,37,38,42,43], six studies received a neutral rating (*i.e.* unclear levels of internal validity and bias) [32–36,39], and three studies received a negative rating [30,40,41]. Interventions were generally well described with clearly defined outcomes. Objective biomarkers were utilised across studies, with the exception of studies that had self-reported measures of satiety [35,36] and gastrointestinal health outcomes [39,40].

3.1.2. Bioactive compounds

A total of 41 studies reported the concentration of bioactive antioxidant compounds (ergosterol, 16 studies [44–59]; ergothioneine, 4 studies [48,60–62]; flavonoids, 22 studies [63–84]) and 16 reported concentrations of polysaccharides (glucans, 9 studies [27,80,84–91]; chitin, 7 studies [27,87,90,92–95]) in *A. bisporus* mushrooms (Table 3). From the 16 papers that reported ergosterol, five also reported Vitamin D₂ (25(OH)D₂) [46,48–51]. Mushroom varieties included WBM (47 studies) [27,46–56,59–66,68–87,89–95], portobello (8 studies) [49,57,58,60,61,85,87,88], BBM (7 studies) [47,48,54,55,67,79,89], and cremini (6 studies) [49,60,61,85,87,88] mushrooms. The majority of studies (79%) reported only one mushroom type, with WBM being the most common (68%), and two studies did not specify the type of mushroom used [44,45]. Mushrooms were mainly cultivated (51 studies) [27,46,48–58,60–83,86–95] and sourced from Europe (24 studies) [27,44,45,50,52,53,55–58,64,67,69,73,74,78,79,86,88–90,93–95] and Asia (19 Studies) [51,59,62,63,65,66,68,71,72,75–77,80–84,87,91]. Other regions included the Americas (6 studies) [48,49,60,61,70,85], Canada (3 studies) [46,47,54] and the United Kingdom (1 study) [92].

3.2. Impact of *A. bisporus* mushroom intake on human health

3.2.1. Serum vitamin D

Studies that reported on the bioavailability of vitamin D from UVB-exposed mushrooms used fresh mushrooms [29,31], dried mushroom extract [30] and mushroom powder [32]. Doses of vitamin D ranged from 8.8 µg/day (352 IU/day) [29], up to 28,000 IU/day (700 µg/day) [31], and study durations ranged from 5 to 12 weeks. A significant increase in serum 25(OH)D₂ was reported in all four RCT studies [29–32], alongside a decrease in serum 25(OH)D₃ reported in two studies [29,32], ($P<.001$ for all). Three studies showed a significant increase in total serum 20(OH)D ($P<.001$ for all) [30–32], and only one study specifically screened people for low levels of vitamin D at baseline [32]. When UVB-exposed mushroom extracts were compared to a daily vitamin D₂ or D₃ supplement (2000 IU/day; 50 µg/day) across a 12-week intervention, no significant differences in overall 25(OH)D levels between the groups were found [30]. At doses of 2000 IU/day, UVB-exposed mushrooms were equivalent to a supplement at increasing total 25(OH)D levels.

3.2.2. Inflammatory markers

Three studies reported on inflammatory markers [33,34,42]. In healthy young women, both 8 g and 16 g doses of mushroom powder

Table 3
Bioactive components in *Agaricus Bisporus* mushrooms

Reference	Type	Mushroom source (wild/cultivated, country)	Mushroom part	Compound (glucan/flavonoid/ergosterol etc.)	Amount
Babu, 2013	WBM	Cultivated, India	Cap	Flavonoids	2.173±0.0007 µg/g
			Stipe	Flavonoids	1.533±0.005 µg/g
Akyüz, 2012	WBM	Cultivated, Turkey	Whole	Myricetin	11.75 µg/g
				Quercetin	0.25 µg/g
				Kaempferol	0.25 µg/g
				Catechin	396.00 µg/g
				Naringenin	1.75 µg/g
				Resveratrol	0.50 µg/g
Tajalli, 2015	WBM	Cultivated/wild, Iran	Whole (wild) [^]	Flavonoids	3.72 (0.0020) mg CE/g
				Anthocyanins	4.7 (1.2) mg CGEs/100 g
				Flavonoids	4.24 (0.0016) mg CE/g
				Anthocyanins	7.7 (0.5) mg CGEs/100 g
				Flavonoids	2.78 (0.0004) mg CE/g
				Anthocyanins	1.13 (0.2) mg CGEs/100 g
				Flavonoids	5.11 (0.0044) mg CE/g
				Anthocyanins	0.15 (0.01) mg CGEs/100 g
			Whole (cultivated)	Flavonoids	3.98 (0.0004) mg CE/g
				Anthocyanins	1.7 (0.2) mg CGEs/100 g
				Flavonoids	4.12 (0.0020) mg CE/g
				Anthocyanins	0.087 (0.1) mg CGEs/100 g
				Flavonoids	4.15 (0.0016) mg CE/g
				Anthocyanins	'very low' (almost 0) mg CGEs/100 g
				Flavonoids	4.94 (0.0028) mg CE/g
				Anthocyanins	4.6 (0.9) mg CGEs/100 g
Singla, 2010	WBM	Cultivated, India	Whole (raw)	Flavonoids (free)	37.12 mg/100 g
				Flavonoids (bound)	64.69 mg/100 g
			Whole (processed)	Flavonoids (free)	35.42 mg/100 g
				Flavonoids (bound)	63.72 mg/100 g
Mircea, 2015	BBM	Cultivated, Romania	Whole	Flavonoids	1.09 (0.02) mg CE/g
					0.97 (0.01) mg CE/g
					1.52 (0.01) mg CE/g
Guizani, 2012	WBM	Cultivated, Oman	Whole	Flavonoids	0.76 (0.05) mg
Jaworska, 2014	WBM	Cultivated, Poland	Whole (fresh)	Flavonoids	142 (8) mg/100 g
			Whole (blanched)	Flavonoids	53 (3) mg/100 g
			Whole (culinary treated)	Flavonoids	35 (5) mg/100 g
Gan, 2013	WBM	Cultivated, Malaysia, Brazil	Extract (60% ethanol)	Flavonoids	1.75 (0.26) mg GAE/g
			Extract (aqueous)	Flavonoids	1.36 (0.11) mg GAE/g
Ganguli, 2006	WBM	Cultivated, India	Whole (raw)	Flavonoids	0.079% (0.004)
			Whole (fried 4 min)	Flavonoids	0.050% (0.002)
			Whole (fried 5 min)	Flavonoids	0.041% (0.004)
			Whole (fried 6 min)	Flavonoids	0.038% (0.006)
Singla, 2012	WBM	Cultivated, India	Whole (raw)	Flavonoids	37.12 mg/100 g
			Whole (2% treated)	Flavonoids	31.54 mg/100 g
			Whole (4% treated)	Flavonoids	31.53 mg/100 g
Öztürk, 2011	WBM	Cultivated, Turkey	Whole	Flavonoids	5.12 (0.55) µg QE/mg
Ozen, 2010	WBM	Cultivated, Turkey		Flavonoids	0.106 (0.006) mg QE/g
				Anthocyanins	0.17 (0.01) mg/mL
Rezaeian, 2015	WBM	Cultivated/wild, Iran	Whole (cultivated)	Flavonoids	6.46 (0.13) mg CE/g
			Whole (cultivated)	Flavonoids	1.11 (0.24) mg CE/g
			Whole (wild) [^]	Flavonoids	4.48 (0.05) mg CE/g
Ng, 2019	WBM	Cultivated, India	Whole (raw)	Flavonoids	78.67 (8.80) mg QE/100 g
			Whole (boiled)	Flavonoids	46.89 (1.25) mg QE/100 g
			Whole (microwaved)	Flavonoids	43.39 (4.66) mg QE/100 g
			Whole (steamed)	Flavonoids	32.83 (4.51) mg QE/100 g
			Whole (pressure-cooked)	Flavonoids	59.11 (10.30) mg QE/100 g
Ng, 2017	WBM	Cultivated, Malaysia	Whole (raw)	Flavonoids	20.2 (2.9) mg Qct/100 g
			Whole (boiled 1.5 min)	Flavonoids	12.2 (2.8) mg Qct/100 g
			Whole (boiled 3 min)	Flavonoids	11.3 (2.7) mg Qct/100 g
			Whole (boiled 4.5 min)	Flavonoids	10.7 (0.7) mg Qct/100 g
			Whole (boiled 6 min)	Flavonoids	9.8 (0.4) mg Qct/100 g
			Whole (microwaved 1.5 min)	Flavonoids	14.3 (2.4) mg Qct/100 g
			Whole (microwaved 3 min)	Flavonoids	7.5 (1.0) mg Qct/100 g
			Whole (microwaved 4.5 min)	Flavonoids	6.1 (1.1) mg Qct/100 g
			Whole (microwaved 6 min)	Flavonoids	4.2 (0.5) mg Qct/100 g
			Whole (steamed 1.5 min)	Flavonoids	11.2 (3.4) mg Qct/100 g
			Whole (steamed 3 min)	Flavonoids	14.4 (5.0) mg Qct/100 g
			Whole (steamed 4.5 min)	Flavonoids	12.0 (1.0) mg Qct/100 g
			Whole (steamed 6 min)	Flavonoids	13.8 (1.0) mg Qct/100 g
			Whole (pressure-cooked 15 min)	Flavonoids	12.7 (0.3) mg Qct/100 g
Barros, 2018	WBM	Cultivated/wild, Portugal	Whole [^]	Flavonoids	1.73 (0.11) mg/g
Buruleanu, 2018	WBM	Cultivated, Romania	Cap	Flavonoids	6.54 (0.00) mg QE/g
				Flavonoids	7.83 (4.18) mg QE/g
			Stipe	Flavonoids	5.23 (0.02) mg QE/g

Table 3 (continued)

Reference	Type	Mushroom source (wild/cultivated, country)	Mushroom part	Compound (glucan/flavonoid/ ergosterol etc.)	Amount			
Khan, 2016 Jagadish, 2009	BBM	Cultivated, India	Cap	Flavonoids	3.26 (0.04) mg QE/g			
			Stipe	Flavonoids	8.43 (0.02) mg QE/g			
	WBM		Whole	Flavonoids	3.5 (0.14) mg QE/g			
			Whole (raw)	Flavonoids	8.05 (0.04) mg QE/g			
			Whole (boiled)	Flavonoids	5.22 (0.06) mg QE/g			
			Whole	Flavonoids	56.76 µg RE/g			
Dhamodhara, 2013 Um, 2014 Palanisamy, 2014	WBM	Cultivated, South Korea	Whole	Flavonoids	16.4 (0.5) mg QE/g			
			Whole (25 °C)*	Flavonoids	15.2 (0.2) mg QE/g			
Choi, 2010	WBM	Korea	Whole	α-Glucan	10.3 (1.0) mg QE/g			
				β-Glucan	1636.8 (17.5) mg naringin/100 g			
			LMW	α-Glucan	27% ^a			
				β-Glucan	25% ^a			
				α-Glucan	26% ^a			
			HMW	β-Glucan	27% ^a			
				α-Glucan	32% ^a			
			Dikeman, 2005	WBM	Cultivated, USA	Raw immature	β-Glucan	29% ^a
							β-Glucan	35% ^a
						Cooked immature	α-Glucan	0% ^a
β-Glucan	50% ^a							
Raw mature	β-Glucan	44% ^a						
	β-Glucan	4.9 mg/100 g						
Cooked mature	α-Glucan	8.97 (0.21) % w/w						
	β-Glucan	1.13 (0.52) % w/w						
Crimini	β-Glucan	7.83 (0.74) % w/w						
	Catechin	15.07 (0.83) mg/g						
Portabella	Tannic acid	11.58 (0.65) mg/g						
	Gallate	9.51 (0.52) mg/g						
Nitschke, 2011a Khan, 2017	WBM	Cultivated, Germany	Raw immature	Catechin	14.98 (0.34) mg/g			
				Tannic acid	11.50 (0.27) mg/g			
			Cooked immature	Gallate	9.45 (0.22) mg/g			
				β-Glucan	0.1%			
			Raw mature	β-Glucan	0.1%			
				β-Glucan	0.1%			
			Cooked mature	β-Glucan	0.1%			
				β-Glucan	0.1%			
			Crimini	β-Glucan	0.1%			
				β-Glucan	0.1%			
Portabella	β-Glucan	0.1%						
	β-Glucan	0.1%						
Nitschke, 2011a Khan, 2017	WBM	Cultivated, Germany	Whole	β-Glucan	0.1%			
				β-Glucan	0.2%			
Singh, 2017	WBM	Cultivated, India	Whole	β-Glucan	2.60 g/100 g			
				Total glucan	10.045 (0.21) g/100 g			
			Portobello	α-Glucan	1.534 (1.56) g/100 g			
				β-Glucan	8.511 (2.45) g/100 g			
Mirończuk-Chodakowska, 2017	Portobello Crimini	Cultivated, Poland	Whole	Total glucan	0.78 g/10 g			
				Chitin	0.12 g/10 g			
			Crimini	Chitin-glucan complex	1.8 g/10 g			
				Total glucan	3.96 (0.64)			
Sari, 2017	WBM	Cultivated, Germany	Cap	Total glucan	3.94 (0.08)			
				β-Glucan	19.20%			
			Stipe	Total glucan	10.051±2.228 g/100 g			
				α-Glucan	1.547±0.378 g/100 g			
Taofiq, 2016 Stojkovic, 2014 Simon, 2011	Unknown Unknown WBM	Portugal Netherlands Cultivated, Canada	Cap	β-Glucan	8.605±2.373 g/100 g			
				Total glucan	14.963 (4.979) g/100 g			
			Stipe	α-Glucan	2.667 (1.224) g/100 g			
				β-Glucan	12.296 (4.077) g/100 g			
Simon, 2011	WBM	Cultivated, Canada	Cap	Total glucan	12.348 (4.514) g/100 g			
				α-Glucan	3.511 (2.383) g/100 g			
			Stipe	β-Glucan	8.837 (3.046) g/100 g			
				Total glucan	14.647 (4.874) g/100 g			
Simon, 2011	WBM	Cultivated, Canada	Cap	α-Glucan	4.568 (2.845) g/100 g			
				β-Glucan	10.079 (2.230) g/100 g			
			Stipe	Ergosterol	44.79±0.37 mg/g			
				Ergosterol	138.74± 0.61 mg/100 g			
Simon, 2011	WBM	Cultivated, Canada	Whole	Ergosterol	578.2±29.8 mg/100 g			
				Vitamin D	5.5±4.6 µg/100 g			

(continued on next page)

Table 3 (continued)

Reference	Type	Mushroom source (wild/cultivated, country)	Mushroom part	Compound (glucan/flavonoid/ergosterol etc.)	Amount		
Shao, 2010	WBM	Canada	Whole (UV light exposed)	Ergosterol	579.5±20.7 mg/100 g		
			Whole (sunlight exposed)	Vitamin D	579.5±20.7 µg/100 g		
			Stage 1	Ergosterol	633.4±17.4 mg/100 g		
			Stage 2	Vitamin D	633.4±17.4 µg/100 g		
			Stage 3	Ergosterol	3.41 mg/g		
			Cap (Stage 3)	Ergosterol	3.32 mg/g		
			Stipe (Stage 3)	Ergosterol	3.01 mg/g		
			BBM	Canada	Stage 1	Ergosterol	3.41 mg/g
					Stage 2	Ergosterol	3.32 mg/g
					Stage 3	Ergosterol	3.01 mg/g
Cap (Stage 3)	Ergosterol	3.30 mg/g					
Stipe (Stage 3)	Ergosterol	2.33 mg/g					
Stipe (Stage 3)	Ergosterol	2.33 mg/g					
Sapozhnikova, 2014	WBM	Cultivated, USA	Extract	Ergosterol	4.66 mg/g		
			Extract	Ergosterol	4.66 mg/g		
			Extract	Ergosterol	2.93 mg/g		
			Extract	Ergosterol	2.93 mg/g		
			Extract	Ergosterol	2.49 mg/g		
			Extract	Ergosterol	2.49 mg/g		
			Extract	Ergosterol	2.71 mg/g		
			Extract	Ergosterol	2.71 mg/g		
			Extract	Ergosterol	2.03 mg/g		
			Extract	Ergosterol	2.03 mg/g		
Phillips, 2011	WBM	Cultivated, USA	Extract (Low UV)	Ergothioneine	0.81–0.92 mg/g		
			Extract (High UV)	Ergosterol	4.6–5.2 mg/g		
			Extract	Vitamin D	179 ± 5 IU/g		
			Extract	Vitamin D	2156± 43 IU/g		
			Extract	Vitamin D	4739± 61 IU/g		
			Extract	Ergothioneine	0.37–0.48 mg/g		
			Extract	Ergosterol	4.6–6.2 mg/g		
			Extract	Vitamin D	179± 4 IU/g		
			Extract	Vitamin D	1942± 30 IU/g		
			Extract	Vitamin D	6292±109 IU/g		
Mattila, 2002	WBM	Cultivated, Finland	Whole	Ergosterol	56.3 mg/100 g		
			Whole	Vitamin D	0.11 µg/100 g		
			Whole	Ergosterol	61.4 mg/100 mg		
			Whole	Vitamin D	0.06 µg/100 g		
			Cap	Ergosterol	62.1 mg/100 g		
			Cap	Vitamin D	0.25 µg/100 g		
Jasinghe, 2005	WBM	Cultivated, Singapore	Cap (UV treated)	Ergosterol	51.1 mg/100 g		
			Cap (UV treated)	Vitamin D	11.2 µg/100 g		
			Whole	Ergosterol	654 mg/100 g		
			Whole	Vitamin D	0 mg/100 g		
			Whole	Vitamin D	4.7–194 µg/100 g		
			Whole	Ergosterol	7.80±0.35 mg/g		
Heleno, 2017	WBM	Cultivated, Portugal	Whole	Vitamin D	12.48±0.28 µg/g		
			Whole	Ergosterol	36.72±0.01 mg/g		
			Whole	Ergosterol	443± 44 mg/100 g; 90% free sterols		
			Cap	Ergosterol	6.12±0.09 mg/g		
			Cap	Ergosterol	6.12±0.09 mg/g		
			Cap	Ergosterol	6.05±0.37 mg/g		
			Cap	Ergosterol	6.11±0.20 mg/g		
			Cap	Ergosterol	5.96±0.16 mg/g		
			Cap	Ergosterol	5.2±0.13 mg/g		
			Cap	Ergosterol	5.2±0.13 mg/g		
Hamann, 2016	WBM	Cultivated, Germany	Cap	Ergosterol	5.4±0.29 mg/g		
			Cap	Ergosterol	5.4±0.29 mg/g		
			Cap	Ergosterol	5.25±0.22 mg/g		
			Cap	Ergosterol	5.2±0.18 mg/g		
			Cap	Ergosterol	5.2±0.18 mg/g		
			Cap	Ergosterol	7.59±0.13 mg/g		
			Cap	Ergosterol	7.59±0.13 mg/g		
			Cap	Ergosterol	7.61± 0.61 mg/g		
			Cap	Ergosterol	7.64±0.31 mg/g		
			Cap	Ergosterol	7.69±0.19 mg/g		
Guan, 2016	WBM	Cultivated, Canada	Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
			Cap	Ergosterol	7.56±0.41 mg/g		
Gasecka, 2018	BBM	Cultivated, Poland	Cap	Ergosterol	7.22± 41 mg/g		
			Cap	Ergosterol	7.35±0.29 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
			Cap	Ergosterol	7.60±0.18 mg/g		
Cardoso, 2017	WBM	Cultivated, Portugal	Cap	Ergosterol	26.4± 1.5 mg/100 g		
			Cap	Ergosterol	9.5± 1.2 mg/100 g		
			Cap	Ergosterol	21.7± 1.2 mg/100 g		
			Cap	Ergosterol	36.1± 3 mg/100 g		
			Cap	Ergosterol	4± 0.7 mg/100 g		
			Cap	Ergosterol	18.4 mg/100 g		
Cardoso, 2019	WBM	Cultivated, Portugal	Cap	Ergosterol	1.1±0.2 mg/100 g		
			Cap	Ergosterol	1.1±0.2 mg/100 g		
			Cap	Ergosterol	17.4±0.1 mg/g		
			Cap	Ergosterol	17.4±0.1 mg/g		
			Cap	Ergosterol	216–250 mg/100 g		
			Cap	Ergosterol	216–250 mg/100 g		
Barreira, 2014	WBM	Cultivated, Portugal	Cap	Ergosterol	352 ± 1 mg/100 g		
			Cap	Ergosterol	352 ± 1 mg/100 g		
			Cap	Ergosterol	77 ± 1 mg/100 g		
			Cap	Ergosterol	77 ± 1 mg/100 g		
			Cap	Ergosterol	77 ± 1 mg/100 g		
			Cap	Ergosterol	77 ± 1 mg/100 g		
Alshammaa, 2017	WBM	Wild, Iraq	Cap	Ergosterol	27.6675% (w/w)		
			Cap	Ergosterol	27.6675% (w/w)		
			Cap	Ergosterol	27.6675% (w/w)		
Chung, 1998	WBM	Cultivated, UK	Cap	Chitin	42%		
			Cap	Chitin	42%		
Hassainia, 2018	WBM	Cultivated, France	Cap	Chitin	7.4± 1.2%		

Table 3 (continued)

Reference	Type	Mushroom source (wild/cultivated, country)	Mushroom part	Compound (glucan/flavonoid/ergosterol etc.)	Amount
Manzi, 2001	WBM	Cultivated, Italy	Stipe	Chitin	6.4±1.4%
			Gills	Chitin	5.9± 1.2%
			Whole (fresh, raw)	β-Glucan	1.4±0.2 mg/100 g
				Chitin	0.6±0.04 g/100 g
			Whole (fresh, cooked)	β-Glucan	4.2± 0.3 mg/100 g
				Chitin	0.7±0.04 g/100 g
			Whole (deep frozen, raw)	β-Glucan	1.2± 0.6 mg/100 g
				Chitin	0.34±0.01 g/100 g
			Whole (deep frozen, cooked)	β-Glucan	3.2±0.8 mg/100 g
				Chitin	0.52±0.02 g/100 g
Nitschke, 2011b Vetter, 2007	WBM	Cultivated, Germany	Extract	Chitin	4.69±0.90 mg/100 g
			Cap (1st flush)	Chitin	7.21±0.51%
	WBM	Cultivated, Germany	Cap (2nd flush)	Chitin	7.16±1.0%
			Cap (3rd flush)	Chitin	5.63±1.02%
			Stipe (1st flush)	Chitin	7.61±0.90%
			Stipe (2nd flush)	Chitin	7.29±1.34%
			Stipe (3rd flush)	Chitin	6.94±2.23%
			Whole	Ergothioneine	0.41±0.18 mg/g
					0.47±0.16 mg/g
					0.15 mg/g
Kalaras, 2017	WBM	Cultivated, USA	Whole	Ergothioneine	0.21±0.01 mg/g
					0.40±0.03 mg/g
					0.45±0.03 mg/kg
Dubost, 2007	WBM	Cultivated, USA	Whole	Ergothioneine	932.7±5.0 mg/kg
Chen, 2012	WBM	Cultivated, Taiwan	Whole	Ergothioneine	

WBM, white button mushroom; BBM, brown button mushroom; LMW, low molecular weight; HMW, high molecular weight; * pressurised-water extraction temperatures; ^ wild mushrooms may naturally receive UV exposure from sunlight compared to cultivated mushrooms unless otherwise specified; a, values estimated from figures; µg, micrograms; CGEs, cyanidin-3-glucoside equivalents; CE, catechin equivalents; QE, quercetin equivalents; GAE, gallic acid equivalents; Qct, quercetin; RE, rutin equivalents; w/w, weight per weight.

increased serum ergothioneine and decreased oxygen radical absorbance capacity (ORAC) [34]. Alternatively, in a 16-week uncontrolled pre-post study using a cooked mushrooms intervention (100 g/day), both serum ergothioneine and ORAC increased ($P=.03$) [42]. When cytokine production was measured after 5 g/day of α-glucans from mushroom extract consumed across a 5-week intervention, tumour necrosis factor (TNF)-α decreased compared to the control ($P=.017$) [33]. However, there were no effects on any other inflammatory markers measured (i.e. interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17, interferon-γ, serum creatinine).

3.2.3. Satiety

Two studies assessed the impact of dietary mushrooms on satiety, and findings were inconsistent [35,36]. In 35 young adults (age 23±4 years), mushroom consumption was associated with lower hunger ($P=.045$), greater fullness ($P=.05$) and decreased prospective food consumption ($P=.03$) compared with a protein-matched beef portion [35]. However, no change in energy intake was observed [35]. Alternatively, in a different sample of mixed-race adults from the USA ($n=47$; age mean (range) 35.5 (18–62) years) mushroom intake was not associated with changes in subjective satiety when compared to a volume-matched, rather than energy-matched, portion of beef [36]. The replacement of mushrooms for beef resulted in a decrease in the total fat and energy intake (total fat 41.1±0.4 g vs. 10.2±0.2 g, $P<.001$; energy 2012±70 kcal vs. 1640±65 kcal, $P<.001$) of the meal, and the lower energy intake from the meal was only partially compensated for at the other eating occasions (11.4±12.0% energy; 7.4±7.7% total fat) [36].

3.2.4. Gastrointestinal health

Consumption of fresh mushrooms [39] and a mushroom extract [40] both showed beneficial effects on stool weight, microbiota, bowel

strain, faecal odour and halitosis (Table 2). No changes were observed in markers of bacterial fermentation (breath H₂, faecal pH and faecal short chain fatty acids) [39] or bowel regularity [40], compared to the control.

3.2.5. Cancer

The association between human consumption of *A. bisporus* mushrooms and cancer was assessed in a case control study [37] and a Phase 1 Clinical Trial [38]. In the case-control study of 1000 females from China (age 59±6 years), consumption of more than 2 g per day of WBM reduced the odds of ovarian cancer by 32% (adjusted OR 0.68 (95% CI, 0.52–0.89) [37]. In a sample of prostate cancer patients, mushroom extract at increased doses (4–14 g extract daily; equivalent to 40–140 g fresh WBM) was associated with decreased total prostate specific antigen (PSA) levels in 36% of patients, with stable PSA levels or no effect in the remaining patients [38]. Minimal side effects were reported and mostly limited to Grade 1 abdominal bloating [38].

3.2.6. Metabolic markers

Two studies reported on metabolic markers of health [41,42]. WBM cooked in olive oil (2 g/kg body weight/day) were associated with significantly lower glucose, total cholesterol, low-density lipoprotein, triglycerides and body weight, and higher high-density lipoprotein, compared to the control ($P<.05$ for all) [41]. However, baseline values were not reported, and the olive oil was only delivered to the treatment group. In a second sample of adults with at least two features of the metabolic syndrome, adiponectin increased after daily consumption of 100 g of cooked mushrooms over the 16-week intervention (7.9±3.2 µg/mL baseline; 8.8±3.5 µg/mL 16 weeks, $P=.03$) [42].

3.2.7. Immune function

The effect of cooked WBM (100 g/day for 7 days) on salivary IgA secretion was measured in 24 healthy adults (age 41.4 ± 11.3 years) [43]. Compared to their usual diet, 100 g of cooked WBM intake for 7 days was associated with increased serum IgA osmolarity ($P < .0001$), secretion rate ($P < .0005$), and concentration ($P < .0005$) [43]. These findings indicate a potential benefit for mucosal immunity.

3.3. Concentration of bioactive compounds in *A. bisporus*

3.3.1. Flavonoids

The majority (95%) of studies reported the total flavonoid content of whole mushrooms, and one study reported individual flavonoids [64] (Table 3). Two studies measured the cap and stipe (*i.e.* the stalk) separately for WBM [63,79] and BBM [79], and five studies investigated the effect of cooking on flavonoid content [69,71,76,77,81]. WBM had the highest concentration of catechins (396.00 $\mu\text{g/g}$) and myricetins (11.75 $\mu\text{g/g}$), and low to negligible quantities of quercetin, kaempferol, naringenin and resveratrol present (0.25–1.75 $\mu\text{g/g}$) [64]. Cooking mushrooms reduced flavonoid concentrations and flavonoid concentration for raw mushrooms was the highest across all studies [69,71,76,77,81]. Cooking methods assessed included blanching [69], frying [71,76], boiling [76,77,81], microwaving [76,77], steaming [76,77] and pressure cooking [76,77]. Only two studies measured the effect of cooking time, on flavonoid content [71,76]. For both boiling and frying, flavonoid content was reduced with cooking time (6 min) [71,76]. For shorter cooking times (1.5 min), microwaving retained the most flavonoids compared to boiling or steaming (70.8%, 60.4% and 55.4% respectively) [76]. When cooking time was extended to 6 min, microwaving retained the least flavonoids compared to other cooking methods (20.8% microwaving, 48.5% boiling, 68.3% steaming) [76].

The mushroom cap had a greater concentration of flavonoids than the stipe. Four out of five analyses from two studies reported a mean of 28.1% greater flavonoid concentration in the WBM cap (range: 4.5–58.4%), compared to the stipe [63,79]. For BBM, the difference between the cap and stipe differed according to the solvent used for the analysis, with the water solvent showing a greater concentration in the cap, and the 50% water-ethanol showing a greater concentration in the stipe [79]. Only one study reported on flavonoids in both WBM and BBM, with the water solvent showing higher concentrations of flavonoids in the BBM, and water-ethanol solvent showing a greater concentration in WBM [79]. Majority of studies (75%) used colorimetric assays [63,65–68,70–76,78,79,81], while the remainder used spectrometry (15%) [69,77,80], high performance liquid chromatography (5%) [64] or an unspecified method (10%) [82,83]. None of the studies reported on flavonoid concentrations by mushroom maturity (*e.g.* WBM compared to Portobello).

3.3.2. Ergosterol and vitamin D

Ergosterol was measured in 16 studies [44–59]. In addition to ergosterol, vitamin D₂ was also measured in five of those studies [46,48–51]. Most studies (67%) that reported on ergosterol and vitamin D content used UVB-exposed mushrooms [46,48–50]. The range of ergosterol concentrations in UVB-exposed whole WBM and BBM were 579.5 mg/100 g–633.4 mg/100 g [46,54] and 722.0 mg/100 g – 769.0 mg/100 g [54], respectively (Table 3). No studies reported ergosterol in UVB-exposed extracts. In non-UV-exposed whole WBM and BBM, the average ergosterol concentration was 714.3 mg/100 g (range 56.3–1740 mg/100 g) [45–47,49–51,53,54,56] and 334.5 mg/100 g (range 203.0–466.0 mg/100 g) [47,54], respectively. In non-UV-exposed WBM and BBM extracts, the range of ergosterol concentration was 4–3672 mg/100 g [44,48,52,55] and 26.4–620 mg/100 g [48,55], respectively. Exposure to UVB light over time consistently increased vitamin D₂ content and decreased ergosterol concentrations [49,54].

Both BBM and cremini mushrooms had a marginally higher quantity of ergosterol compared to WBM in two studies (BBM 466 mg/100 g vs. WBM 341 mg/100 g [47]; cremini 61.4 mg/100 g vs. WBM 56.3 mg/100 g [49]). None of the studies investigated the effect of cooking method or mushroom maturity on ergosterol content. Except one study which compared the portobello cap against whole WBM [49] and found a marginally higher concentration of ergosterol in the portobello cap (62.1 mg/100 g) compared to the WBM (56.3 mg/100 g) [49].

3.3.3. Ergothioneine

Four studies measured ergothioneine content [48,60–62]. One used both WBM and BBM extracts [48], while the remaining studies used whole mushrooms [60–62]. Whole mushrooms contained an average ergothioneine content of 0.43 ± 0.25 mg/g. There were no clear trends among the two studies that compared the ergothioneine content by type of whole mushroom (whole WBM, cremini and portobello mushrooms) [60,61]. However, WBM extract had a greater concentration of ergothioneine (0.81–0.92 mg/g) than BBM extract (0.37–0.48 mg/g) [48]. None of the studies reported on the effect of cooking method or the part of the mushroom body (*i.e.* cap vs. stipe) on ergothioneine concentrations.

3.3.4. Glucans

Nine papers measured and reported on glucans as either total [80,84,87–89,91], alpha- [27,80,84,87–89,91], and/or beta- [27,80,84–89,91]. Glucans were reported using a variety of methods (% w/w, %, and g/100 g), making direct comparisons across studies difficult. When total, alpha- and beta-glucans were compared across the cap and stipe of WBM and BBMs, a higher concentration of glucans was reported in the stipe [89]. Studies which measured both alpha and beta-glucans reported that the most prevalent glucans present in mushrooms are beta-glucans, which account for (mean \pm SD) $75.0 \pm 17.8\%$ of the total glucan concentration [80,84,89,91]. BBM had a marginally higher concentration of glucans than WBM [89]. No differences in beta-glucan concentration were reported by mushroom maturity or cooking method [85], and all studies used whole mushrooms.

3.3.5. Chitin

Chitin was measured in seven studies using WBM [27,87,90,92–95], with high variability in reported values. Chitin content ranged from 0.005 g/100 g to 1.2 g/100 g for whole mushroom [27,87,90], 6.4% to 42% in the stipe [92,93,95], 7.2% to 7.4% in the cap [93,95], 5.9% gills [93] and 0.005 g/100 g for the extract [94]. Cooking increased chitin content regardless of preparation technology, with comparable values in fresh and canned samples (fresh: raw 0.6 ± 0.04 g/100 g vs. cooked 0.7 ± 0.04 g/100 g; deep frozen: raw 0.34 ± 0.01 g/100 g vs. cooked 0.52 ± 0.02 g/100 g; canned: raw 0.61 ± 0.05 g/100 g vs. cooked 0.74 ± 0.06 g/100 g) [90]. No studies measured chitin in other mushroom types.

4. Discussion

This scoping literature review systematically summarised the evidence from human intervention trials and biochemical studies that reported on the health effects and bioactive compounds in *A. bisporus* mushrooms. Results confirmed that *A. bisporus* mushrooms are a rich source of beta-glucans, antioxidants and vitamin D, with a wide variability in values reported by mushroom type, cooking time and method, and exposure to UVB across studies. Several beneficial effects of *A. bisporus* consumption exist for metabolic syndrome, gastrointestinal health and cancer, with the strongest evidence of a health effect on improving vitamin D status of individuals. All studies reported that the consumption of UVB-exposed mushrooms was as effective at increasing and maintaining total serum 25(OH)D levels as

vitamin D supplements, in individuals with and without vitamin D deficiency at baseline. Despite the wide range of health benefits reported, the evidence is still quite limited and further research is warranted, specifically for inflammatory and immune function where results are promising.

The biologically distinct and nutritionally unique properties of mushrooms make them a powerful food choice to improve human health. Unlike plants, mushrooms have high concentrations of ergosterol in their cell walls [4], and when both fresh and dried varieties of mushrooms are exposed to UVB radiation, ergosterol is transformed to pre-vitamin D₂, then converted to vitamin D₂ [30,96]. Findings confirm UVB-exposed mushrooms contain vitamin D₂ in a very bioavailable form that is relatively stable during storage and cooking, making them an ideal non-animal food source of vitamin D. Mushrooms also contain significant proportions of beta-glucans. We found that beta-glucans accounted for approximately 75% of total glucan concentrations in *A. bisporus* mushrooms with a volume of 8–12 g/100 g dry weight, which is substantially higher than the 3–8 g/100 g dry weight found in oats, 1.3–2.7 g/100 g dry weight in rye, and 2–20 g/100 g dry weight in barley. A number of international food governing bodies (including Food Standards Australia New Zealand, U. S. Food and Drug Administration, European Food Safety Authority, Health Canada's Food Directorate, and Singapore Food Agency) have approved a high level health claim based on the relationship between the consumption of 3 g of beta-glucans (from oats or barley) and blood cholesterol, with no such claim available for mushrooms. Given the significant proportions of beta-glucans reported in mushrooms, further research in this area is warranted to confirm the potential health effects induced by beta-glucans from mushrooms specifically.

Studies identified by this review suggest that the consumption of *A. bisporus* mushrooms may improve both components of the metabolic syndrome and gastrointestinal health. However, the only study that measured markers of metabolic syndrome provided mushrooms alongside olive oil, which exerts its own beneficial effect on human health [97]. The impact of mushrooms on satiety was inconsistent, which is likely a result of the lack of consistent comparator groups used (*i.e.* volume matched vs. energy matched portion of beef). While whole mushrooms and extracts were associated with bowel function, further research is required to explore if these effects are linked to any further health improvement as existing research did not identify any change in short chain fatty acids or bacterial fermentation.

Two included studies reported that *A. bisporus* mushrooms reduced the risk and progression of ovarian and prostate cancers, respectively. This suggests that these mushrooms may have a role as adjuvant therapy for cancer treatment. The mechanism of action for this effect may be related to the immunomodulating and anti-tumour effects of beta-glucans, ergothioneine and ergosterol [5]. Beta-glucans have been shown to have immune-stimulating effects [20,21], and ergothioneine is an immune modifier with antioxidant and cytoprotective properties [98,99]. This review found that consumption of whole WBM improved mucosal immunity in one study *via* increased serum IgA osmolarity and adiponectin [42], which may have a role in the prevention of malignancy and improved prognosis [100]. Decreased levels of ergothioneine in both blood and plasma have been observed in neurodegenerative, cardiovascular and kidney diseases [99], while increased ergothioneine concentrations may beneficially modulate the tumour microenvironment [101]. Similarly, ergosterol is an immunologically active lipid that can induce pyroptosis [102]. Although included studies regarding the effect of human *A. bisporus* mushroom consumption on immunity and cancer had high internal validity, further robust RCTs are required to confirm their cancer preventative and treatment effects in diverse samples alongside traditional therapies.

A large number of published studies reported the presence of flavonoids in *A. bisporus* mushrooms. These highlight large variability

in the measurement of total flavonoids, ranging from as little as 5.68 mg rutin equivalents per 100 g [80], up to 1636 mg per 100 g [83] in whole WBM. Estimates of daily flavonoid intake from across USA, European and Australian databases range from 209 mg to 1017 mg per day [103]. Recent evidence suggests that mushrooms may not contain flavonoids at all due to (i) the absence of genes required for their biosynthesis, and (ii) the lack of flavonoids detected when using analytic methods with higher levels of sensitivity and specificity such as high-performance liquid chromatography *versus* colorimetric assays [104]. Currently, there are no validated methods for the identification and quantification of flavonoids in foods and plants, and thus quantification of flavonoids has been inconsistent between studies [105]. Gil Raminéz et al. (2016) provide convincing evidence to suggest that another compound is being detected by assays claiming to detect flavonoids [104]. They showed that ergosterol demonstrated cross-reactivity with quercetin in a colorimetric assay, giving a positive reading in the detectable range when no quercetin was present [104]. As the majority (75%) of studies in this review measured flavonoids using colorimetric assays, caution is required when interpreting these values. Although flavonoids may or may not be present in mushrooms, a strong correlation between total flavonoids and antioxidant activity has been found [61]. Therefore, whatever the measured compound/s is, it has biological activity similar to that of flavonoids *in vitro*. If not a flavonoid, the compound could be ergosterol, as ergosterol from BBM and WBM has been highly correlated with total antioxidant activity ($R^2=0.89$) [47] and could account for the antioxidant activity previously observed [61]. In turn, it may further contribute to the cancer preventative effects of *A. bisporus* mushrooms.

4.1. Implications for future research

Opportunities exist for future research to confirm the causative relationship between the consumption of whole WBM *versus* extracts on human inflammatory and immune function, and its anti-cancer effects. Prior to being adopted into clinical practice and public health initiatives, replication of existing studies in other population groups is required to confirm the impact of *A. bisporus* mushrooms on human health including satiety, gastrointestinal function including its effect on the microbiota, and metabolic syndrome. Initial human studies are required to replicate findings from *in vitro* and animal studies which suggest *A. bisporus* mushrooms may improve mental health and cognitive function, as none conducted in humans have reported on these health outcomes. Further research is required to fully elucidate the bioactive compounds in mushrooms using vigorous analytical methods, such as nuclear magnetic resonance spectroscopy, and expand the immunological markers and bioactive compounds being tested.

4.2. Limitations

The strengths of this review relate to the broad systematic literature search strategy used to identify the available evidence to answer the research question. This is the first review to systematically synthesise the evidence from published human trials on *A. bisporus* mushroom specifically, and its consumption on health outcomes, while further reporting on the bioactive compounds that may explain these effects. This review is further strengthened by the development of and adherence to an evidenced based protocol and comprehensive evaluation of the methodological quality of included human studies. It is limited by many studies that reported inadequate details related to sample size or power calculations. The lack of such details may confound data particularly relating to the reliability of effect sizes. There was large variability in bioactive measurements reported in mushrooms, which may be due to differing analytic methods with

varying degrees of sensitivity and specificity. Lastly, despite a growing interest in the relationship between mushrooms and health, only a small number of studies (<4 studies) have been published for each health outcome, despite over 300 narrative reviews having been published on mushrooms and health using *in vitro* and animal models. This reduces confidence in the reported effects and limits the generalisability of the conclusions to the general population.

5. Conclusion

A. bisporus mushrooms are sources of beta-glucans, ergosterol, ergothioneine, vitamin D and an antioxidant compound usually reported as flavonoids; with varying concentrations depending on the type of mushroom, cooking method and duration, and UVB exposure. UVB-exposed mushrooms increase and maintain serum 25 (OH)D levels to a similar degree as vitamin D supplements. Further, the evidence shows *A. bisporus* may lower the risk of cancer, and could potentially improve metabolic syndrome, immune function and gastrointestinal health. Due to the small number of studies examining each health outcome and the lack of replication of reported results, further research is required to confirm these effects on health to enable findings to be adopted into clinical practice.

Acknowledgements

The authors thank Mr. David Honeyman of Bond University, Australia for his advice and guidance with refining the search strategy. This study received funding from Hort Innovation. Hort Innovation provided general feedback on the proposed review strategy; and had no contribution to the final search strategy, data collection, quality assessment, implementation or interpretation of results and drafting of the manuscript. All authors have made a significant contribution to the research and development of the manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jnutbio.2020.108453>.

References

- Feeney MJ, Miller AM, Roupas P. Mushrooms – biologically distinct and nutritionally unique: exploring a “third food kingdom”. *Nutr Today*. 2014;49:301–7.
- Feeney MJ, Dwyer J, Hasler-Lewis CM, et al. Mushrooms and health summit proceedings. *J Nutr* 2014;144:1128S–36S.
- Koyyalamudi SR, Jeong SC, Cho KY, Pang G. Vitamin B12 is the active corrinoid produced in cultivated white button mushrooms (*Agaricus bisporus*). *J Agricul Food Chem*. 2009;57:6327–33.
- Cardwell G, Bornman JF, James AP, Black LJ. A review of mushrooms as a potential source of dietary vitamin D. *Nutrients*. 2018;10:1498.
- Roupas P, Keogh J, Noakes M, et al. The role of edible mushrooms in health: evaluation of the evidence. *J Funct Foods*. 2012;4:687–709.
- Valverde ME, Hernández-Pérez T, Paredes-López O. Edible mushrooms: improving human health and promoting quality life. *Int J Microbiol*. 2015;2015:376387.
- Wu D, Pae M, Ren Z, et al. Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. *J Nutr*. 2007;137:1472–7.
- Guggenheim AG, Wright KM, Zwickey HL. Immune modulation from five major mushrooms: application to integrative oncology. *Integr Med (Encinitas)*. 2014;13:32–44.
- Hsu CH, Liao YL, Lin SC, et al. The mushroom *Agaricus Blazei* Murill in combination with metformin and gliclazide improves insulin resistance in type 2 diabetes: a randomized, double-blinded, and placebo-controlled clinical trial. *J Altern Complement Med*. 2007;13:97–102.
- De Silva D, Rapior S, Hyde K, Bahkali A. Medicinal mushrooms in prevention and control of diabetes mellitus. *Fungal Divers*. 2012;56:1–29.
- Ganesan K, Xu B. Anti-obesity effects of medicinal and edible mushrooms. *Molecules*. 2018;23:E2880.
- Zhao S, Zhang S, Zhang W, et al. First demonstration of protective effects of purified mushroom polysaccharide-peptides against fatty liver injury and the mechanisms involved. *Sci Reports*. 2019;9:13725.
- Henriques G, Helm C, Busato A, Simeone M. Lipid profile and glycemic response of rats fed on a semi-purified diet supplemented with *Agaricus brasiliensis* mushroom. *Acta Sci Anim Sci*. 2016;38:71–9.
- Talpur NA, Echard BW, Fan AY, et al. Antihypertensive and metabolic effects of whole Maitake mushroom powder and its fractions in two rat strains. *Mol Cell Biochem*. 2002;237:129–36.
- Erjavec I, Brkljacic J, Vukicevic S, et al. Mushroom extracts decrease bone Resorption and improve bone formation. *Int J Med Mushrooms*. 2016;18:559–69.
- Jayachandran M, Xiao J, Xu B. A critical review on health promoting benefits of edible mushrooms through gut microbiota. *Int J Mol Sci*. 2017;18:E1934.
- Chen S, Yong T, Zhang Y, et al. Anti-tumor and anti-angiogenic ergosterols from *Ganoderma lucidum*. *Front Chem*. 2017;5:85.
- Li X, Wu Q, Xie Y, et al. Ergosterol purified from medicinal mushroom *Amauroderma rude* inhibits cancer growth in vitro and in vivo by up-regulating multiple tumor suppressors. *Oncotarget*. 2015;6:17832–46.
- Nkodo A. A Systematic Review of in-vivo Studies on Dietary Mushroom Supplementation for Cognitive Impairment (P14–021–19). *Curr Dev Nutr* 2019;3:nzz052.P14–021–19.
- Rop O, Mlcek J, Jurikova T. Beta-glucans in higher fungi and their health effects. *Nutr Rev*. 2009;67:624–31.
- Wong KH, Lai C, Cheung P. Immunomodulatory activities of mushroom sclerotial polysaccharides. *Food Hydrocoll*. 2011;25:150–8.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6:e1000097.
- Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med*. 2018;169:467–73.
- Mavergames C. Covidence [systematic review software]; 2013.
- Research International, Team Strategic Business Development. Evidence analysis manual: Steps in the academy evidence analysis process; 2016.
- Volman JJ, Helsper JPF, Wei S, et al. Effects of mushroom-derived beta-glucan-rich polysaccharide extracts on nitric oxide production by bone marrow-derived macrophages and nuclear factor-kappaB transactivation in Caco-2 reporter cells: can effects be explained by structure? *Mol Nutr Food Res*. 2010;54:268–76.
- Palanisamy M, Aldars-Garcia L, Gil-Ramirez A, et al. Pressurized water extraction of beta-glucan enriched fractions with bile acids-binding capacities obtained from edible mushrooms. *Biotechnol Prog*. 2014;30:391–400.
- Lee NK, Aan B. Optimization of ergosterol to vitamin D₂ synthesis in *Agaricus bisporus* powder using ultraviolet-B radiation. *Food Sci Biotechnol*. 2016;25:1627–31.
- Stephensen CB, Zerofsky M, Burnett DJ, et al. Ergocalciferol from mushrooms or supplements consumed with a standard meal increases 25-hydroxyergocalciferol but decreases 25-hydroxycholecalciferol in the serum of healthy adults. *J Nutr*. 2012;142:1246–52.
- Keegan RH, Lu Z, Bogusz JM, et al. Photobiology of vitamin D in mushrooms and its bioavailability in humans. *Dermatoendocrinol*. 2013;5:165–76.
- Urban P, Singler F, Ihorst G, et al. Bioavailability of vitamin D₂ from UVB-irradiated button mushrooms in healthy adults deficient in serum 25-hydroxyvitamin D: a randomized controlled trial. *Eur J Clin Nutr*. 2011;65:965–71.
- Shanely RA, Nieman DC, Knab AM, et al. Influence of vitamin D mushroom powder supplementation on exercise-induced muscle damage in vitamin D insufficient high school athletes. *J Sports Sci*. 2014;32:670–9.
- Volman JJ, Mensink RP, van Griensven LJ, Plat J. Effects of alpha-glucans from *Agaricus bisporus* on ex vivo cytokine production by LPS and PHA-stimulated PBMCs; a placebo-controlled study in slightly hypercholesterolemic subjects. *Eur J Clin Nutr*. 2010;64:720–6.
- Weigand-Heller AJ, Kris-Etherton PM, Beelman RB. The bioavailability of ergothioneine from mushrooms (*Agaricus bisporus*) and the acute effects on antioxidant capacity and biomarkers of inflammation. *Prev Med*. 2012;54 (Suppl):S75–8.
- Hess JM, Wang Q, Kraft C, Slavin JL. Impact of *Agaricus bisporus* mushroom consumption on satiety and food intake. *Appetite*. 2017;117:179–85.
- Cheskin LJ, Davis LM, Lipsky LM, et al. Lack of energy compensation over 4 days when white button mushrooms are substituted for beef. *Appetite*. 2008;51:50–7.
- Lee AH, Pasalich M, Su D, et al. Mushroom intake and risk of epithelial ovarian cancer in southern Chinese women. *Int J Gynecol Cancer*. 2013;23:1400–5.
- Twardowski P, Kanaya N, Frankel P, et al. A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: roles of cytokines and myeloid-derived suppressor cells for *Agaricus bisporus*-induced prostate-specific antigen responses. *Cancer*. 2015;121:2942–50.
- Hess J, Wang Q, Gould T, Slavin J. Impact of *Agaricus bisporus* mushroom consumption on gut health markers in healthy adults. *Nutrients*. 2018;10:1402.
- Nishihira J, Nishimura M, Tanaka A, et al. Effects of 4-week continuous ingestion of champignon extract on halitosis and body and fecal odor. *J Tradit Complement Med*. 2017;7:110–6.
- Abd-alwahab WIA, Al-dulaimi FKY, Abdulqader AT. Effect of mushroom cooked in olive oil on some physiological and biochemical parameters of human. *Eurasia J Biosci*. 2018;12:393–7.
- Calvo MS, Mehrotra A, Beelman RB, et al. A retrospective study in adults with metabolic syndrome: diabetic risk factor response to daily consumption of *Agaricus bisporus* (white button mushrooms). *Plant Foods Hum Nutr*. 2016;71:245–51.
- Jeong SC, Koyyalamudi SR, Pang G. Dietary intake of *Agaricus bisporus* white button mushroom accelerates salivary immunoglobulin a secretion in healthy volunteers. *Nutrition*. 2012;28:527–31.

- [44] Taofiq O, Calhelha RC, Heleno SA, et al. The contribution of phenolic acids to the anti-inflammatory activity of mushrooms: screening in phenolic extracts, individual parent molecules and synthesized glucuronated and methylated derivatives. *Food Res Int*. 2015;76:821–7.
- [45] Stojkovic D, Reis FS, Glamoclija J, et al. Cultivated strains of *Agaricus bisporus* and *A. brasiliensis*: chemical characterization and evaluation of antioxidant and antimicrobial properties for the final healthy product–natural preservatives in yoghurt. *Food Funct*. 2014;5:1602–12.
- [46] Simon RR, Phillips KM, Horst RL, Munro IC. Vitamin D mushrooms: comparison of the composition of button mushrooms (*Agaricus bisporus*) treated postharvest with UVB light or sunlight. *J Agric Food Chem*. 2011;59:8724–32.
- [47] Shao S, Hernandez M, Kramer JK, et al. Ergosterol profiles, fatty acid composition, and antioxidant activities of button mushrooms as affected by tissue part and developmental stage. *J Agric Food Chem*. 2010;58:11616–25.
- [48] Sapozhnikova Y, Byrdwell WC, Lobato A, Romig B. Effects of UV-B radiation levels on concentrations of phyosterols, ergothioneine, and polyphenolic compounds in mushroom powders used as dietary supplements. *J Agric Food Chem*. 2014;62:3034–42.
- [49] Phillips KM, Ruggio DM, Horst RL, et al. Vitamin D and sterol composition of 10 types of mushrooms from retail suppliers in the United States. *J Agric Food Chem*. 2011;59:7841–53.
- [50] Mattila P, Lampi AM, Ronkainen R, et al. Sterol and vitamin D₂ contents in some wild and cultivated mushrooms. *Food Chem*. 2002;76:293–8.
- [51] Jasinghe VJ, Perera CO. Distribution of ergosterol in different tissues of mushrooms and its effect on the conversion of ergosterol to vitamin D₂ by UV irradiation. *Food Chem*. 2005;92:541–6.
- [52] Heleno SA, Rudke AR, Calhelha RC, et al. Development of dairy beverages functionalized with pure ergosterol and mycosterol extracts: an alternative to phytosterol-based beverages. *Food Funct*. 2017;8:103–10.
- [53] Hammann S, Vetter W. Method development for the determination of free and esterified sterols in button mushrooms (*Agaricus bisporus*). *J Agric Food Chem*. 2016;64:3437–44.
- [54] Guan W, Zhang J, Yan R, et al. Effects of UV-C treatment and cold storage on ergosterol and vitamin D₂ contents in different parts of white and brown mushroom (*Agaricus bisporus*). *Food Chem*. 2016;210:129–34.
- [55] Gąsecka M, Magdziak Z, Siwulski M, Mleczek M. Profile of phenolic and organic acids, antioxidant properties and ergosterol content in cultivated and wild growing species of *Agaricus*. *Eur Food Res Technol*. 2018;244:259–68.
- [56] Cardoso RVC, Fernandes A, Oliveira MBPP, et al. Development of nutraceutical formulations based on the mycelium of *Pleurotus ostreatus* and *Agaricus bisporus*. 2017;8:2155–64.
- [57] Cardoso RVC, Fernandes A, Barreira JCM, et al. Effectiveness of gamma and electron beam irradiation as preserving technologies of fresh *Agaricus bisporus* Portobello: a comparative study. *Food Funct*. 2019;278:760–6.
- [58] Barreira JCM, Oliveira MBPP, Ferreira ICFR. Development of a novel methodology for the analysis of ergosterol in mushrooms. *Food Anal Methods*. 2014;7:217–23.
- [59] Alshammaa DAS. Phytochemical investigation and quantitative comparison of ergosterol between *Agaricus bisporus* and *pleurotus ostreatus* by HPLC and GC-MS methods. *Int J Pharm Sci Rev Res*. 2017;44:215–20.
- [60] Kalaras MD, Richie JP, Calcagnotto A, Beelman RB. Mushrooms: a rich source of the antioxidants ergothioneine and glutathione. *Food Chem*. 2017;233:429–33.
- [61] Dubost NJ, Ou B, Beelman RB. Quantification of polyphenols and ergothioneine in cultivated mushrooms and correlation to total antioxidant capacity. *Food Chem*. 2007;105:727–35.
- [62] Chen SY, Ho KJ, Hsieh YJ, et al. Contents of lovastatin, γ -aminobutyric acid and ergothioneine in mushroom fruiting bodies and mycelia. *LWT*. 2012;47:274–8.
- [63] Babu DR, Rao GN. Antioxidant properties and electrochemical behavior of cultivated commercial Indian edible mushrooms. *J Food Sci Technol*. 2013;50:301–8.
- [64] Akyüz M, O'nganer AN, Erecevit P, Kirbag S. Flavonoid contents and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity of some edible mushrooms from Turkey: *A. Bisporus* and *Pleurotus* Spp. *Curr Top Nutraceutical Res*. 2012;10:133–6.
- [65] Tajalli F, Malekzadeh K, Soltanian H, et al. Antioxidant capacity of several Iranian, wild and cultivated strains of the button mushroom. *Braz J Microbiol*. 2015;46:769–76.
- [66] Singla R, Ganguli A, Ghosh M. Antioxidant activities and polyphenolic properties of raw and osmotically dehydrated dried mushroom (*Agaricus bisporus*) snack food. *Int J Food Prop*. 2010;13:1290–9.
- [67] Mircea C, Cioanca O, Iancu C, et al. In vitro antioxidant activity of some extracts obtained from *agaricus bisporus* brown, *pleurotus ostreatus* and *fomes fomentarius*. *Farmacina*. 2015;63:927–33.
- [68] Guizani N, Waly ML. Mushroom extract protects against hydrogen peroxide-induced toxicity in hepatic and neuronal human cultured cells. *Pak J Biol Sci*. 2012;15:1069–74.
- [69] Jaworska G, Pogoń K, Bernaś E, Duda-Chodak A. Nutraceuticals and antioxidant activity of prepared for consumption commercial mushrooms *agaricus bisporus* and *pleurotus ostreatus*. *J Food Qual*. 2014;38:111–22.
- [70] Gan CH, Nurul Amira B, Asmah R. Antioxidant analysis of different types of edible mushrooms (*agaricus bisporus* and *agaricus brasiliensis*). *Int Food Res J*. 2013;20:1095–102.
- [71] Ganguli A, Ghosh M, Singh N. Antioxidant activities and total phenolics of pickles produced from the edible mushroom, *Agaricus bisporus*. *J Culinary Sci Tech*. 2006;5:131–42.
- [72] Singla R, Ganguli A, Ghosh M. Physicochemical and nutritional characteristics of organic acid-treated button mushrooms (*Agaricus bisporus*). *Food Bioprocess Tech*. 2012;5:808–15.
- [73] Ozturk M, Duru ME, Kivrak S, et al. In vitro antioxidant, anticholinesterase and antimicrobial activity studies on three *Agaricus* species with fatty acid compositions and iron contents: a comparative study on the three most edible mushrooms. *Food Chem Toxicol*. 2011;49:1353–60.
- [74] Ozen T, Darcan C, Aktop O, Turkekul I. Screening of antioxidant, antimicrobial activities and chemical contents of edible mushrooms wildly grown in the black sea region of Turkey. *Comb Chem High Throughput Screen*. 2010;14:72–84.
- [75] Rezaeian S, Saadatmand S, Sattari TN, Mirshamsi A. Antioxidant potency of Iranian newly cultivated wild mushrooms of *agaricus* and *pleurotus* species. *Biomed Res*. 2015;26:534–42.
- [76] Ng ZX, Tan WC. Impact of optimised cooking on the antioxidant activity in edible mushrooms. *J Food Sci Technol*. 2017;54:4100–11.
- [77] Ng ZX, Rosman NF. In vitro digestion and domestic cooking improved the total antioxidant activity and carbohydrate-digestive enzymes inhibitory potential of selected edible mushrooms. *J Food Sci Technol*. 2019;56:865–77.
- [78] Barros L, Falcão S, Baptista P, et al. Antioxidant activity of *Agaricus* sp. mushrooms by chemical, biochemical and electrochemical assays. *Food Chem*. 2008;111:61–6.
- [79] Buruleanu LC, Radulescu C, Georgescu AA, et al. Statistical characterization of the phytochemical characteristics of edible mushroom extracts. *Anal Lett*. 2018;51:1039–59.
- [80] Khan AA, Gani A, Ahmad M, et al. Mushroom varieties found in the Himalayan regions of India: antioxidant, antimicrobial, and antiproliferative activities. *Food Sci Biotechnol*. 2016;25:1095–100.
- [81] Jagadish LK, Venkata Krishnan V, Shenbhagaraman R, Kaviyaranan V. Comparative study on the antioxidant, anticancer and antimicrobial property of *Agaricus bisporus* (J. E. Lange) Imbach before and after boiling. *Afr J Biotechnol*. 2009;8:654–61.
- [82] Dhamodharan G, Mirunalini S. A detail study of phytochemical screening, antioxidant potential and acute toxicity of *Agaricus bisporus* extract and its chitosan loaded nanoparticles. *J Pharm Res*. 2013;6:818–22.
- [83] Um MY, Park JH, Gwon SY, et al. *Agaricus bisporus* attenuates dextran sulfate sodium-induced colitis. *J Med Food*. 2014;17:1383–5.
- [84] Choi SJ, Lee YS, Kim JK, et al. Physiological activities of extract from edible mushrooms. *Korean J Food & Nutr*. 2010;39:1087–96.
- [85] Dikeman CL, Bauer LL, Flickinger EA, Fahey Jr GC. Effects of stage of maturity and cooking on the chemical composition of select mushroom varieties. *J Agric Food Chem*. 2005;53:1130–8.
- [86] Nitschke J, Modick H, Busch E, et al. A new colorimetric method to quantify beta-1,3-1,6-glucans in comparison with total beta-1,3-glucans in edible mushrooms. *Food Chem*. 2011;127:791–6.
- [87] Singh AK, Dutta D. Extraction of chitin-Glucan complex from *Agaricus bisporus*: characterization and antibacterial activity. *J Polym Mater*. 2017;34:1–9.
- [88] Mironczuk-Chodakowska I, Witkowska AM, Zujko ME, Terlikowska KM. Quantitative evaluation of 1,3,1,6 beta-D-glucan contents in wild-growing species of edible polish mushrooms. *Rocz Panstw Zaki Hig*. 2017;68:281–90.
- [89] Sari M, Prange A, Lelley JL, Hambitzer R. Screening of beta-glucan contents in commercially cultivated and wild growing mushrooms. 2017;216:45–51.
- [90] Manzi P, Aguzzi A, Pizzoferrato L. Nutritional value of mushrooms widely consumed in Italy. *Food Chem*. 2001;73:321–5.
- [91] Kahn AA, Gani A, Masoodi FA, et al. Structural, rheological, antioxidant, and functional properties of β -glucan extracted from edible mushrooms *Agaricus bisporus*, *Pleurotus ostreatus* and *Coprinus atramentarius*. *Bioact Carbohydr Diet Fibre*. 2017;11:67–74.
- [92] Chung LY, Schmidt RJ, Hamlyn PF, et al. Biocompatibility of potential wound management products: hydrogen peroxide generation by fungal chitin/chitosans and their effects on the proliferation of murine L929 fibroblasts in culture. *J Biomed Mater Res*. 1998;39:300–7.
- [93] Hassainia A, Satha H, Boufi S. Chitin from *Agaricus bisporus*: extraction and characterization. *Int J Biol Macromol*. 2018;117:1334–42.
- [94] Nitschke J, Altenbach HJ, Malolepszy T, Molleken H. A new method for the quantification of chitin and chitosan in edible mushrooms. *Carbohydr Res*. 2011;346:1307–10.
- [95] Vetter J. Chitin content of cultivated mushrooms *Agaricus bisporus*, *Pleurotus ostreatus* and *Lentinula edodes*. *Food Chem*. 2007;102:6–9.
- [96] Jasinghe VJ, Perera CO, Sablani SS. Kinetics of the conversion of ergosterol in edible mushrooms. *J Food Eng*. 2007;79:864–9.
- [97] George ES, Marshall S, Mayr HL, et al. The effect of high-polyphenol extra virgin olive oil on cardiovascular risk factors: a systematic review and meta-analysis. *Crit Rev Food Sci Nutr*. 2019;59:2772–95.
- [98] Yoshida S, Shime H, Funami K, et al. The anti-oxidant ergothioneine augments the immunomodulatory function of TLR agonists by direct action on macrophages. *PLoS One*. 2017;12:e0169360.
- [99] Halliwell B, Cheah IK, Tang RMY. Ergothioneine – a diet-derived antioxidant with therapeutic potential. *FEBS Lett*. 2018;592:3357–66.
- [100] Katira A, Tan PH. Evolving role of adiponectin in cancer-controversies and update. *Cancer Biol Med*. 2016;13:101–19.
- [101] Yoshida S, Shime H, Matsumoto M, et al. Anti-oxidative amino acid L-ergothioneine modulates the tumor microenvironment to facilitate adjuvant vaccine immunotherapy. *Front Immunol*. 2019;10:671.
- [102] Rodrigues ML. The multifunctional fungal ergosterol. *mBio* 2018;9:e01755–18.
- [103] Peterson J, J., Dwyer JT, Jacques PF, McCullough ML. Improving the estimation of flavonoid intake for study of health outcomes. *Nutr Rev*. 2015;73:553–76.
- [104] Gil-Ramirez A, Pavo-Caballero C, Baeza E, et al. Mushrooms do not contain flavonoids. *J Funct Foods*. 2016;25:1–13.
- [105] Balentine DA, Dwyer JT, Erdman Jr JW, et al. Recommendations on reporting requirements for flavonoids in research. *Am J Clin Nutr*. 2015;101:1113–25.